Illumina’s China FOMO, with BridgeCross Bio’s Matt Marlowe

<p>Episode 13</p><p>China’s burgeoning biotech and genomics markets make for the ultimate compare and contrast. </p><p>Like the US, it has regional hotspots, intense competition, and a big company whose success has helped seed a second wave of startups, many of whom are now breaking through. </p><p>However, the clinical system is both vast and vastly different, marketing approaches can seem stuck in the past, and success abroad — rather than at home — may end up being the difference between making it and getting caught in the churn. </p><p>That’s according to Matthew Marlowe, who runs BridgCross Bio, a digital publication seeking to provide insight into China’s biotech industry for a Western audience. Earlier this month, Marlowe spent two weeks traveling across China to meet with and discover companies based there. </p><p>We discuss some of the new tech he’ll be watching and what it means for companies based in the US and Europe, especially Illumina, which has been hamstrung by high-level government policy that has made it difficult to grow revenue there. </p><p>Make sure to listen all the way through for a new tidbit I’ve extracted about Illumina CEO Jacob Thaysen’s May trip to China at the invitation of the White House. </p><p>Marlowe is also founder of Genapse, a marketing company for life science companies.</p>